Vapotherm (VAPO: NYSE) Investor Relations Material

Overview

Vapotherm, Inc., a cutting-edge medical technology company, is passionately committed to the development and commercialization of innovative high velocity therapy products for respiratory distress patients worldwide. With a wide array of precision flow system offerings, such as HVT 2.0, Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox, Vapotherm delivers heated, humidified, and oxygenated air at a high velocity through a small-bore nasal interface. The company also provides complementary products, such as the Vapotherm Transfer Unit, which enables patients to be transferred between care areas while receiving therapy, and the Q50 compressor, which provides compressed air essential to running the precision flow systems. Furthermore, Vapotherm offers aerosol aeroneb adaptor, aerosol disposable patient circuit, tracheostomy adaptors, and ProSoft cannula, which provides gentle contact with the skin, as well as disposable products comprising single-use disposables and nasal interfaces, and Oxygen Assist Modules, which helps clinicians maintain oxygen levels within a target range. The company provides its top-of-the-line products to hospitals, and its headquarters is in Exeter, New Hampshire, after being founded in 1993.